Acquired Company

MoonLake Immunotherapeutics AG closed its business combination with Helix Acquisition Corp. on 4/5/2022; following the merger, Helix changed its name to MoonLake Immunotherapeutics and the company began trading on Nasdaq under the ticker MLTX.

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland. Show more

Dorfstrasse 29, Zug, 6300, Switzerland

https://www.moonlaketx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.323B

52 Wk Range

$5.95 - $62.75

Previous Close

$18.68

Open

$19.04

Volume

1,410,397

Day Range

$17.86 - $19.10

Enterprise Value

124.4M

Cash

380.5M

Avg Qtr Burn

-44.54M

Insider Ownership

10.85%

Institutional Own.

81.28%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Sonelokimab Details Hidradenitis suppurativa	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sonelokimab Details Psoriatic arthritis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sonelokimab Details Hidradenitis suppurativa	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sonelokimab Details Palmoplantar pustulosis	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sonelokimab Details Psoriatic arthritis and Axial spondyloarthritis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sonelokimab Details Axial spondyloarthritis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.